Our Services

Real World Evidence

Fresh opportunities to identify, demonstrate and defend the value of your therapy — from strategy through to post-approval safety studies.

RWE strategy and study design planning

RWE / 01

Strategy, Planning and Study Design

Every effective RWE programme starts with a clear strategy aligned to the questions that matter most to regulators, payers and clinical decision-makers.

Our cross-functional team combines epidemiology, biostatistics and health-economics expertise to design fit-for-purpose studies that generate the evidence your stakeholders need — whether that is a pre-launch burden-of-illness study or a post-approval comparative-effectiveness analysis.

RWE / 02

Natural History and Disease Burden Studies

We design and manage prospective registries and retrospective chart-review programmes across rare-disease, chronic and oncology indications. Our approach combines rigorous protocol development with pragmatic site engagement to ensure high-quality data collection that withstands regulatory and HTA scrutiny.

Natural history study data collection
Patient preference and PRO research

RWE / 03

Patient Preference and PRO Research

Understanding what matters most to patients is increasingly central to regulatory and reimbursement decisions.

We run discrete-choice experiments, best-worst scaling studies and patient-reported outcome measure (PROM) validation programmes that give your dossier the patient-voice evidence regulators and HTA bodies expect.

RWE / 04

Post-Approval Safety and Effectiveness Studies

We manage Post-Authorisation Safety Studies (PASS), Post-Authorisation Effectiveness Studies (PAES) and long-term safety registries to the standards expected by the EMA, MHRA and other global regulators. From protocol design through to final study report, our team ensures robust pharmacovigilance integration and timely regulatory deliverables.

Post-approval safety study monitoring
Health economics analytics and HEOR

RWE / 05

Analytics, HEOR and Regulatory Engagement

Our health-economics and outcomes-research (HEOR) analysts deliver cost-effectiveness models, budget-impact analyses and comparative-effectiveness reviews that support your market-access strategy.

We also provide scientific-advice preparation and HTA-engagement support, helping you present a compelling, evidence-based value story to NICE, G-BA, HAS and other national bodies.